[fam-] trastuzumab deruxtecan (DS-8201) - Daiichi Sankyo
DS-8201: Data presentation from P2 DESTINY-Breast01 trial (NCT03248492) for (HER2)-positive breast cancer at SABCS (December 10-14, 2019) (Daiichi Sankyo) - Apr 27, 2019 - FY 2018 Results 
P2 data
https://www.daiichisankyo.com/media_investors/investor_relations/ir_calendar/files/005439/FY2018%20Q4_Presentation%20Material.pdf
 
Apr 27, 2019
 
 
9622fc3f-3190-43b8-8bb2-740d4a79fa4c.jpg